Fermion Oy DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Fermion invests in flow chemistry capability

02 Jan 2025

// PRESS RELEASE

Fermion - leader in sustainable API manufacturing

29 Oct 2024

// PRESS RELEASE

Green chemistry at Fermion

20 Aug 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

ChemOutsourcing

Exhibiting

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

15 Corporate Content #SupplierSpotlight, 2 Data Compilation #PharmaFlow, 31 News #PharmaBuzz

media
15 Corporate Content #SupplierSpotlight
2 Data Compilation #PharmaFlow
31 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

52 All APIs, 28 USDMF, 22 CEP/COS, 12 JDMF, 13 KDMF, 21 NDC API, 8 VMF, 30 Listed APIs

52 All APIs
28 USDMF
22 CEP/COS
12 JDMF
13 KDMF
21 NDC API
8 VMF
30 Listed APIs

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

FINISHED DOSAGE FORMULATIONS

588 FDF Dossiers, 7 FDA Orange Book, 534 Europe, 47 Canada

588 FDF Dossiers
7 FDA Orange Book
534 Europe
47 Canada

INTERMEDIATES

9 All Intermediates

9 All Intermediates

KEY PRODUCTS

Benserazide Hydrochloride, Dabrafenib Mesylate, Dexmedetomidine Hydrochloride, Methotrexate, Nintedanib Esylate, Sodium Cromoglicate

Benserazide Hydrochloride
Dabrafenib Mesylate
Dexmedetomidine Hydrochloride
Methotrexate
Nintedanib Esylate
Sodium Cromoglicate

SERVICES

Analytical, API Manufacturing, Drug Product Manufacturing, API & Drug Product Development, Packaging

pharmaServices
Analytical
- 1 Analytical Method Development
API Manufacturing
Drug Product Manufacturing
API & Drug Product Development
- 3 API Development
Packaging
- 7 Contract Services

KEY SERVICES

API Contract Manufacturing Services, API Micronization Services, Clinical Supply of APIs, CMO for Hormonal Gels & Solutions, Cytotoxic API Contract Manufacturing, Controlled Substance API Manufacturing

API Contract Manufacturing Services
API Micronization Services
Clinical Supply of APIs
CMO for Hormonal Gels & Solutions
Cytotoxic API Contract Manufacturing
Controlled Substance API Manufacturing

INSPECTIONS & REGISTRATIONS

20 FDA, 3 EDQM, 4 GDUFA

inspections
20 FDA
3 EDQM
4 GDUFA

With Fermion, start the journey of your innovative API.

About

Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.

CPhI South East AsiaCPhI South East Asia

Industry Trade Show

Not Confirmed

16-18 July, 2025

MITEC, Kuala Lumpur, Malaysia
ChemOutsourcingChemOutsourcing

Industry Trade Show

Exhibiting

08-10 September, 2025

Parsippany NJ, Hilton
Contract PharmaContract Pharma

Industry Trade Show

Exhibiting

18-19 September, 2025

Hyatt Regency New Brunswick, NJ

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Finland

Address

Koivu-Mankkaan tie 6 A, FI-02200 Espoo

Telephone

+358 104261

fermionSales@fermion.fi

Website

https://www.fermion.fi/

https://fi.linkedin.com/company/fermion-oy

YouTube

http://www.youtube.com/@fermionoy2799

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Presentation

GMP Certificate 2024

Japan Accreditation Certificate for Oulu Plant

Open PDF

Upload

Japan Accreditation Certificate for Hanko Plant

List of Inspections

Company Introduction

Oulu Unit

Quality & On-Time Delivery

Turku Unit

Hanko Unit 4 Virtual Tour

Delivering Consistent API Quality

Fermion R&D

Hanko Unit 4

HPAPI Solutions

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 3358

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 3982

NEWS #PharmaBuzz

Fermion invests in flow chemistry capability

02 Jan 2025

// PRESS RELEASE

Fermion - leader in sustainable API manufacturing

29 Oct 2024

// PRESS RELEASE

Green chemistry at Fermion

20 Aug 2024

// PRESS RELEASE

Fermion has completed first investment for new Mfg capacity for APIs

12 Mar 2024

// PRFESS RELEASE

Ami Organics inks agreement with Fermion for two additional APIs

19 Dec 2023

// INDIAN PHARMA POST

Fermion has received CEPs for Benserazide HCL and Entacapone

19 Oct 2023

// PRESS RELEASE

ALL APIs

Click the button for full data set

01

Alprazolam

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

Click Us!

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Azathioprine

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Formoterol Fumarate

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF CN

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Hydroxychloroquine Sulphate

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Irinotecan Hydrochloride

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF CN

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Mercaptopurine

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Methotrexate

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF ASMF, BR

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Sodium Cromoglicate

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF CN

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Buspirone Hydrochloride

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

USDMF

CEP/COS

JDMF EU-WC NDC

KDMF VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Fluoxetine Hydrochloride

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

Product Not Available For Sales

USDMF

CEP/COS

JDMF EU-WC NDC

KDMF

VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

01

Alprazolam

Finland

Finland

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

Fermion Oy

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Darolutamide

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Bayer AG

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

U.S. FDA approves third indication of darolutamide for prostate cancer

Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.

Product Name : Nubeqa

Product Type : HPAPI

Upfront Cash : Inapplicable

June 03, 2025

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Recombinant Human Albumin

Therapeutic Area : Trauma (Emergency, Injury, Surgery)

Highest Development Status : Phase I

Recipient : Shilpa Medicare

Deal Size : Undisclosed

Deal Type : Agreement

DEALS_DEV

Orion and Shilpa Medicare Partner on Recombinant Human Albumin In Europe

Details : Orion will gain exclusive right to distribute, market and sell Shilpa’s sRbumin, a recombinant human albumin in Europe.

Product Name : sRbumin

Product Type : Protein

Upfront Cash : Undisclosed

May 23, 2025

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

03 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Apomorphine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : Phase III

Recipient : Criceto Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

DEALS_DEV

Orion And Criceto Sign License Deal for APORON Spray in Parkinson’s Disease

Details : Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.

Product Name : Aporon

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

April 25, 2025

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

04 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Undisclosed

Therapeutic Area : Oncology

Highest Development Status : Discovery Platform

Partner/Sponsor/Collaborator : Invenra

Deal Size : Undisclosed

Deal Type : Agreement

DEALS_DEV

Orion, Invenra Sign Deal for Bispecific Antibody Cancer Therapeutics

Details : Under the terms of the agreements, Invenra will leverage its B-Body bispecific antibody platform from monoclonal antibody discovery to treat cancer.

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Undisclosed

January 30, 2025

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

05 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Darolutamide

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Bayer AG

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Orion's Partner Bayer Submits Darolutamide Application in China for Third Indication

Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.

Product Name : Nubeqa

Product Type : HPAPI

Upfront Cash : Inapplicable

January 07, 2025

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

06 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Ganaxolone

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Marinus Pharmaceuticals

Deal Size : $1.5 million

Deal Type : Termination

DEALS_DEV

Orion and Marinus Terminate Agreement for Ganaxolone in Europe

Details : under the termination agreement, Marinus regains Ztalmy (ganaxolone) rights in Europe. It is approved for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder.

Product Name : Ztalmy

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 30, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

07 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Undisclosed

Therapeutic Area : Technology

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : Evariste

Deal Size : Undisclosed

Deal Type : Collaboration

DEALS_DEV

Orion and Evariste Collaborate to Design Inhibitors for Undisclosed Target

Details : The collaboration will allow Evariste to utilize its innovative Frobenius Discovery platform to design small-molecule inhibitors for a target selected by Orion.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 10, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

08 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : ODM-111

Therapeutic Area : Neurology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges

Details : ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.

Product Name : ODM-111

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 24, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

09 Orion Corporation

Finland

Discovery Europe

Not Confirmed

Lead Product(s) : Darolutamide

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Bayer AG

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Orion's Partner Bayer Submits Darolutamide Application in EU for Third Indication

Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.

Product Name : Nubeqa

Product Type : HPAPI

Upfront Cash : Inapplicable

October 14, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

10 Fermion Oy

Finland

ChemOutsourcing

Exhibiting

With Fermion, start the journey of your innovative API.

Lead Product(s) : FZ008-145

Therapeutic Area : Neurology

Highest Development Status : IND Enabling

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Fermion Announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

Details : FZ008-145 is a highly selective second-generation Nav1.8 inhibitor, offering powerful, non-addictive pain relief advantages. It is being evaluated in preclinical studies for acute and chronic pain.

Product Name : FZ008-145

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 01, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

Only 10 entries up to this point, click to access all